Unlock the Potential of Allogeneic T Cell Medicine
ProTcell, the first ever T cell Progenitors based biotherapy-platform
Make High Science T cell Therapies Affordable and Accessible
Smart Immune is the first clinical-stage biotherapeutics company focused on delivering the rapid, multipotent curative power of T Cell Progenitors to patients in life threatening conditions.
Once transplanted to patient, those T cell Progenitors so called ProTcell, differentiate quickly into polyclonal T cell in thymus recipient to reset a fully functional immune system and ensure a fast, multipotent defense from all pathogens and cancer cells.
Smart Immune proprietary ProTcell platform is in clinical stage and has been designed to adress all hurdles of allogenic T cell medicine in ones: infections, GvHD and relapses to significantly improve overall survival for thousands of patients.
This ground breaking technology is applicable to all cell and gene therapies involving T cells, enabling fast improved clinical outcome for patients. With one clinical trial on Severe combined immuno-deficiencies and a clinical trial on high risk AML already in clinic in Europe, a clinical trial for Acute Leukemia to be initiated shortly in the US and a milli-fluidic automation project enabling bioproduction scalability, Smart Immune aims to make allo HSCT medicine safer, more effective, and more affordable.
Based in Paris, Smart Immune integrates a collaboration with Necker Enfants Malades Hospital cell and gene therapy teams bringing ground-breaking scientific, clinical and development expertise. With the demonstrated track records of its founders, Marina Cavazzana, MD, PhD, and Isabelle André, PhD, Smart Immune is committed to change Patient prognosis.
The Immune T Cell system is the most efficient weapon for fighting life threatening cancers and infections
What if we could reset it without inducing adverse events ?
Bringing allo HSCT curative power to patients in life threatening conditions without inducing adverse events
T Cell Progenitors: a new generation of allogenic T cell medicine enabling a reset of T cell immune system to fight cancers and infections
A rapid efficiency without inducing adverse events to improve significantly life expectancy and quality
Partnership set to develop fully-automated , miniaturized cell-culture bioreactors to produce HSC-derived cell-culture products at scale
Our latest news and updates
Smart Immune Announces FDA Orphan Drug Status, IND Acceptance and Fast-Track Designation to Commence Phase 1/2 Clinical Trial of Proprietary Allogeneic T cell progenitor Product SMART 101 (ProTcell™) for AML and ALL
First ever clinical trial of any T-cell progenitor product
Representing a decade of research and development, Smart Immune is thrilled to bring this ground-breaking science into human clinic with the objectives to change Allogeneic HSCT prognosis for Patients in life threatening conditions. Smart Immune plan to open a clinical trial for high-risk leukemia in one of the top US cancer center by the end of the year 2021. Based on partnership with expert medical centers in Europe, two additional clinical studies in Severe combined immune deficiencies (SCID) and high-risk Acute Myeloid Leukemia (AML) aim to further demonstrate the power of this T cell progenitor (ProTcellTM) platform .
Paris Biotech Santé reinforces its support to Smart Immune
Smart Immune is very pleased to annonce the extension of its labs and offices spaces enabling the company to face GMP , regulatory and clinical ramp up for the ProTcellTM platform development.